The results demonstrate that VEGF‐A, along with other angiogenic and inflammatory markers such as bFGF, PDGF, and IL‐6, serves as a valuable biomarker for diagnosis and prognosis in patients with ALL. Here, FGF2 is linked to acute lymphoblastic leukemia.